Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Stock Short Interest Climbs 95.6%

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 164,782 shares, a growth of 95.6% from the September 15th total of 84,256 shares. Based on an average daily volume of 2,143,151 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CELZ. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Weiss Ratings cut Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

Creative Medical Technology Stock Down 4.3%

CELZ traded down $0.03 on Wednesday, hitting $0.79. The company had a trading volume of 71,537 shares, compared to its average volume of 3,260,549. The company has a market cap of $5.17 million, a PE ratio of -0.38 and a beta of 2.06. Creative Medical Technology has a 12-month low of $0.62 and a 12-month high of $6.25. The business’s fifty day simple moving average is $1.04 and its 200 day simple moving average is $1.54.

Creative Medical Technology (NASDAQ:CELZ) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, analysts anticipate that Creative Medical Technology will post -1.18 earnings per share for the current fiscal year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc is a clinical-stage biotechnology company focused on developing regenerative medicine and cellular therapies. The company’s research uses adult stem cells and other cell-based approaches intended to address conditions with limited treatment options, including immune, neurological, metabolic and urological disorders.

Its development programs have included CaverStem, an autologous bone marrow-derived cell therapy platform being investigated for erectile dysfunction, as well as ImmCelz and NeuroCelz programs designed to explore cell-based treatments for immune-related and neurological conditions.